Abstract
INTRODUCTION: The hepatitis A virus (HAV) is a common cause of acute hepatitis, while glucose-6-phosphate dehydrogenase (G6PD) deficiency is a widespread enzyme disorder that predisposes individuals to haemolysis and hyperbilirubinemia. We report a case of a G6PD-deficient patient with hepatitis A-induced acute renal failure (ARF), highlighting the role of plasmapheresis and haemodialysis in management. CASE DESCRIPTION: A 40-year-old male with G6PD deficiency and hypertension was transferred for further care after presenting with fever, diarrhoea and jaundice. Laboratory results showed severe haemolysis and elevated bilirubin (70 μmol/l); hepatitis A serology was positive. The patient developed acute liver failure and ARF, with creatinine reaching 7.3 mg/dl. Plasmapheresis and haemodialysis were initiated, leading to stabilisation of renal function and a significant decrease in bilirubin by six weeks post-discharge. DISCUSSION: G6PD deficiency increases the risk of haemolysis, especially during infections such as hepatitis A. This can lead to severe hyperbilirubinemia and complications including bile cast nephropathy. In this case, plasmapheresis effectively reduced bilirubin and inflammatory mediators, while haemodialysis addressed renal dysfunction. Together, these therapies were crucial in stabilising renal function. CONCLUSION: Bile cast nephropathy is an important cause of kidney injury in severe hyperbilirubinemia. This case highlights the effectiveness of plasmapheresis and haemodialysis in managing the condition and supporting renal recovery, especially in the absence of established treatment guidelines. LEARNING POINTS: Bile cast nephropathy is a significant yet underrecognised cause of acute kidney injury, often associated with severe hyperbilirubinemia in the setting of acute liver failure.In this case, glucose-6-phosphate dehydrogenase (G6PD) deficiency combined with hepatitis A-induced haemolysis led to elevated bilirubin levels, contributing to kidney injury.This case highlights the importance of extracorporeal therapies in managing bile cast nephropathy and promoting renal function recovery, particularly in the absence of standard treatment guidelines.